Rhythm Pharmaceuticals Stock News

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) concluded the trading at $8.83 on Friday, December 03 with a fall of -4.02% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $9.20 and 5Y monthly beta was reading 1.43 with its price kept floating in the Rhythm Pharmaceuticals Inc. (RYTM) Forecast: Revisiting The Past To Gain Insights For The Future Read More »

Millennium Management LLC lowered its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 13.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,816 shares of the companys stock after selling 23,711 shares during the period. Millennium Management []

Credit Suisse AG trimmed its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.5% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 23,802 shares of the companys stock after selling 1,654 shares during the quarter. Credit Suisse AGs holdings in Rhythm Pharmaceuticals were worth $467,000 []

Charles Schwab Investment Management Inc. raised its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 267,631 shares of the companys stock after acquiring an additional 15,409 shares during the quarter. Charles Schwab Investment Management []

Charles Schwab Investment Management Inc. increased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 6.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 267,631 shares of the companys stock after buying an additional 15,409 shares during the period. Charles Schwab Investment Management Inc.s holdings in []

Equities research analysts forecast that Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) will report earnings of ($0.99) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Rhythm Pharmaceuticals earnings. The lowest EPS estimate is ($1.08) and the highest is ($0.90). Rhythm Pharmaceuticals reported earnings of ($0.79) per share during the same []

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)s share price was down 7% during mid-day trading on Tuesday . The company traded as low as $12.26 and last traded at $12.30. Approximately 9,488 shares were traded during trading, a decline of 97% from the average daily volume of 371,667 shares. The stock had previously closed at $13.23. A number []

BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM ), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company''s supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS) or Alström syndrome. The FDA granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2022. "The acceptance for filing of our supplemental application by the FDA marks an important step in our efforts to address the unmet needs and bring IMCIVREE to patients and families living with Bardet-Biedl syndrome and Alström syndrome," said Linda Shapiro, M.D., Ph.D., Chief Medical Officer of Rhythm Pharmaceuticals. "The FDA''s decision to grant Priority Review to the application aligns with our belief in the potential of IMCIVREE to deliver clinically meaningful and statistically significant reductions in body weight and hunger for patients with BBS and Alström syndrome while also substantially improving quality of life for these patients and their families." A Priority Review designation is granted by the FDA for the evaluation of drug applications that may offer significant improvements in the safety or effectiveness of the treatment, prevention or diagnosis of a serious disease.

Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q3 2021 Results - Earnings Call Transcript

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare geneti

BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare geneti

-- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger --   -- Updated result

-- New subgroup analysis of Phase 3 data show setmelanotide achieved statistically significant weight loss and hunger reduction compared with placebo at 14 weeks in patients with Bardet-Biedl syndrome

BOSTON, Sept. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued on Wednesday, September 21 by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), please note that the symbol ▼ was erroneously omitted from t